Measles vaccines, available since the early 1960s, have dramatically decreased the
incidence of measles in many parts of the world. However, measles elimination has not …

Context.—Measles causes serious morbidity in infants, with the highest risk among those
who are 6 to 12 months of age. In the United States, measles vaccine has been given at age …

Measles hemagglutinin-inhibiting and neutralizing antibody titers are lower in women young
enough to have been immunized by vaccination than in older women. In the children of both …

Passively acquired antibody may interfere with the active antibody response to live viral
vaccines such as measles and rubella. To evaluate the duration of this inhibitory effect, we …

Measles mortality and measles vaccine efficacy were determined during outbreaks in three
Gambian villages. There were 146 cases of measles among 1073 children younger than 11 …

Background. Shifts in peak measles incidence to children< 12 months old and the
associated high mortality support the study of an early 2-dose measles vaccine regimen …

The duration of immunity following measles vaccination of 2882 immunized children has
been investigated in a closed region of China for 15 years. A total of 1002 of the children …

Maternal and cord measles and rubella antibodies were compared in 15 populations from
Brazil, Ecuador, Chile, India, Jordan, Nigeria, South Africa, Taiwan, and the United States …

Background. Given the high infant measles mortality rate, there is interest in whether a
measles immunization regimen beginning at< 12 months of age provides lasting immunity …

Measles vaccine cannot give high sero-conversion rates in developing countries. The high
birth rates characteristic of these countries lead to infection at a very early age, thus making …